MapLight Therapeutics (MPLT) Cash from Operations (2024 - 2025)

MapLight Therapeutics (MPLT) reported Cash from Operations of 46829000.0 for Q4 2025, down 117.93% on a YoY basis from 261163133.14 in Q4 2024, and down 117.93% sequentially from 21488000.0 in Q4 2024.

MapLight Therapeutics (MPLT) Cash from Operations (2024 - 2025) Analysis & Trends

MapLight Therapeutics (MPLT) has 2 years of Cash from Operations data on file, last reported at 46829000.0 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Operations (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -19.59 Mn
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -2.49 Mn
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 201.34 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 1.43 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 1.08 Bn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -354.17 Mn
10 MapLight Therapeutics 314.07 Mn 314.07 Mn - -46.83 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -46.83 Mn
Dec 31, 2025 -46.83 Mn
Dec 31, 2024 -21.49 Mn
Dec 31, 2024 -21.49 Mn